Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma.
Chari A, Cho HJ, Dhadwal A, Morgan G, La L, Zarychta K, Catamero D, Florendo E, Stevens N, Verina D, Chan E, Leshchenko V, Laganà A, Perumal D, Mei AH, Tung K, Fukui J, Jagannath S, Parekh S. Chari A, et al. Among authors: verina d. Blood Adv. 2017 Aug 21;1(19):1575-1583. doi: 10.1182/bloodadvances.2017007427. eCollection 2017 Aug 22. Blood Adv. 2017. PMID: 29296798 Free PMC article.
Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m2.
Barley K, Sanchez L, Cho HJ, Parekh S, Madduri D, Richter J, Isola L, Goldstein T, Dhadwal A, Zarychta K, Sanchez GM, Catamero D, Verina D, Florendo E, Yum MH, La L, Gullie J, Chan E, Jagannath S, Chari A. Barley K, et al. Among authors: verina d. Am J Hematol. 2020 Feb;95(2):E51-E54. doi: 10.1002/ajh.25695. Epub 2019 Dec 22. Am J Hematol. 2020. PMID: 31814152 Free article. Clinical Trial. No abstract available.
A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma.
Van Oekelen O, Parekh S, Cho HJ, Vishnuvardhan N, Madduri D, Richter J, Ip C, Lau K, Florendo E, Mancia IS, Thomas J, Verina D, Chan E, Zarychta K, La L, Strumolo G, Melnekoff DT, Leshchenko VV, Kim-Schulze S, Couto S, Wang M, Pierceall WE, Thakurta A, Laganà A, Jagannath S, Chari A. Van Oekelen O, et al. Among authors: verina d. Leuk Lymphoma. 2020 Sep;61(9):2208-2215. doi: 10.1080/10428194.2020.1805111. Epub 2020 Aug 19. Leuk Lymphoma. 2020. PMID: 32812822 Clinical Trial.
Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients.
Aleman A, Van Oekelen O, Upadhyaya B, Beach K, Kogan Zajdman A, Alshammary H, Serebryakova K, Agte S, Kappes K, Gleason CR, Srivastava K; PVI/MM/Seronet Study Group; Almo S, Cordon-Cardo C, Krammer F, Merad M, Jagannath S, Wajnberg A, Simon V, Parekh S. Aleman A, et al. Cancer Cell. 2022 May 9;40(5):441-443. doi: 10.1016/j.ccell.2022.03.013. Epub 2022 Apr 6. Cancer Cell. 2022. PMID: 35390296 Free PMC article. No abstract available.
Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation.
Elnaggar M, Agte S, Restrepo P, Ram M, Melnekoff D, Adamopoulos C, Stevens MM, Kappes K, Leshchenko V, Verina D, Jagannath S, Poulikakos PI, Parekh S, Laganà A. Elnaggar M, et al. Among authors: verina d. J Hematol Oncol. 2022 Aug 17;15(1):109. doi: 10.1186/s13045-022-01330-3. J Hematol Oncol. 2022. PMID: 35978321 Free PMC article.
Correction: Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation.
Elnaggar M, Agte S, Restrepo P, Ram M, Melnekoff D, Adamopoulos C, Stevens MM, Kappes K, Leshchenko V, Verina D, Jagannath S, Poulikakos PI, Parekh S, Laganà A. Elnaggar M, et al. Among authors: verina d. J Hematol Oncol. 2023 May 8;16(1):52. doi: 10.1186/s13045-023-01449-x. J Hematol Oncol. 2023. PMID: 37158935 Free PMC article. No abstract available.
Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple Myeloma.
Aleman A, van Kesteren M, Zajdman AK, Srivastava K, Cognigni C, Mischka J, Chen LY, Upadhyaya B, Serebryakova K, Nardulli JR, Lyttle N, Kappes K, Jackson H, Gleason CR, Oostenink A, Cai GY, Van Oekelen O; PVI/MM/Seronet Study Group; van Bakel H, Sordillo EM, Cordon-Cardo C, Merad M, Jagannath S, Wajnberg A, Simon V, Parekh S. Aleman A, et al. EBioMedicine. 2023 Dec;98:104886. doi: 10.1016/j.ebiom.2023.104886. Epub 2023 Nov 22. EBioMedicine. 2023. PMID: 37995467 Free PMC article.
Regression of smoldering myeloma with treatment of Gaucher disease.
Barley K, Parekh A, Salam S, Mendu DR, Shukla RP, Vatti D, Verina D, Stauffer C, Salib C, El Jamal S, Teruya-Feldstein J, Duffield AS, Leshchenko VV, Jagannath S, Balwani M, Parekh S. Barley K, et al. Among authors: verina d. Blood Adv. 2024 Apr 9;8(7):1634-1638. doi: 10.1182/bloodadvances.2023012304. Blood Adv. 2024. PMID: 38285963 Free PMC article. No abstract available.
A Focus on Newly Diagnosed Multiple Myeloma.
Brigle K, Verina D, Faiman B. Brigle K, et al. Among authors: verina d. J Adv Pract Oncol. 2022 Jul;13(Suppl 4):7-14. doi: 10.6004/jadpro.2022.13.5.10. Epub 2022 Jul 28. J Adv Pract Oncol. 2022. PMID: 35937466 Free PMC article.
13 results